Skip to main content
. 2016 May 12;7(27):41637–41649. doi: 10.18632/oncotarget.9317

Figure 1. Cisplatin resistant cells are glutamine dependent.

Figure 1

A and B. [C14]-2DG and [H-3]GLN uptake in ovarian cancer cells with and without cisplatin treatment (2uM), normalized to cell number. (A) Increased [C14]-DG uptake was observed in cisplatin surviving A2780 and OV81.2 cells after 48 hr which was not observed in the cisplatin resistant CP70 and CP10 cell lines. No further increase in tracer uptake is found when the resistant cell lines are treated with cisplatin. (B) Baseline [H3]GLN uptake is 2-fold higher in the cisplatin resistant CP70 compared to A2780 and 3-fold higher in CP10 cells compared to OV81.2 cells. GLN uptake is increased in the sensitive but not the resistant cell lines after 48 hr cisplatin treatment (p<0.01). Experiments were performed in triplicate and repeated 3 times. Uptake is normalized to cell number. Graphs represent mean (boxes) and SD (bars; n=9). C. Western blot showing increased glutamine transporter ASCT2 and glutaminase (GLS) expression in CP70 and CP10 cells compared to the sensitive A2780 and OV81.2, respectively (p< 0.01) D, E. Western blot showing increasing levels of GLS and ASCT2 protein in response to cisplatin treatment in sensitive cell lines, and no change in platinum resistant cells.